menu
    • menu
    [{"orgOrder":0,"company":"Leucid Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LEU011","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leucid Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leucid Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Leucid Bio \/ Inapplicable"},{"orgOrder":0,"company":"Leucid Bio","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"LEU011","moa":"NKG2D receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Leucid Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leucid Bio \/ Leucid Bio","highestDevelopmentStatusID":"5","companyTruncated":"Leucid Bio \/ Leucid Bio"},{"orgOrder":0,"company":"Leucid Bio","sponsor":"ImaginAb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"89Zr-crefmirlimab","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Leucid Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leucid Bio \/ Leucid Bio","highestDevelopmentStatusID":"4","companyTruncated":"Leucid Bio \/ Leucid Bio"},{"orgOrder":0,"company":"Leucid Bio","sponsor":"Leucid Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"LEU011","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Leucid Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leucid Bio \/ Leucid Bio","highestDevelopmentStatusID":"4","companyTruncated":"Leucid Bio \/ Leucid Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by Leucid Bio

    Menu

    Leucid Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Leucid Bio

                            United Kingdom arrow
                            CPhI Korea
                            Not Confirmed

                            Leucid Bio

                            United Kingdom arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LEU011

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 05, 2024

                            Lead Product(s) : LEU011

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Leucid Bio

                            United Kingdom arrow
                            CPhI Korea
                            Not Confirmed

                            Leucid Bio

                            United Kingdom arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LEU011,89Zr-crefmirlimab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : ImaginAb

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with Leucid Bio

                            Details : Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET tracer, 89Zr crefmirlimab berdoxam, to Leucid for use in its basket study in solid tumors, with LEU011 targeting NKG2DL, Autolog...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 04, 2023

                            Lead Product(s) : LEU011,89Zr-crefmirlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : ImaginAb

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Leucid Bio

                            United Kingdom arrow
                            CPhI Korea
                            Not Confirmed

                            Leucid Bio

                            United Kingdom arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LEU011

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Great Ormond Street Hospital

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Leucid Bio And Great Ormond Street Hospital Enter Commercial Agreement At New Gene Therapy Manufacturing Centr...

                            Details : The agreement is to manufacture Leucid Lead asset, LEU011 (autologous CAR T-cell therapy), a lateral CAR targeting NKG2D ligands, for the treatment of solid tumours and haematological malignancies utilising facilities and quality assurance services at th...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 16, 2023

                            Lead Product(s) : LEU011

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Great Ormond Street Hospital

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Leucid Bio

                            United Kingdom arrow
                            CPhI Korea
                            Not Confirmed

                            Leucid Bio

                            United Kingdom arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LEU011

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Lonza Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the Cocoon Platform for Automated Manufacturing...

                            Details : Under the terms of the collaboration, Leucid will utilise Lonza as its preferred manufacturer, aiming to deliver high quality cell therapies quickly and cost-effectively to patients in a decentralized manufacturing model including its lead product, LEU-0...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 02, 2021

                            Lead Product(s) : LEU011

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Lonza Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth